The 2023-2028 Outlook for Carpet and Rug Shampoos in India

This study covers the latent demand outlook for carpet and rug shampoos across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, th...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for C-Arms in India

This study covers the latent demand outlook for c-arms across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share t...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Cardiovascular Therapeutics in India

This study covers the latent demand outlook for cardiovascular therapeutics across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Cardiovascular Drugs in India

This study covers the latent demand outlook for cardiovascular drugs across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the p...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Cardiac Safety Services in India

This study covers the latent demand outlook for cardiac safety services across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, th...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Cardiac Rhythm Management Devices in India

This study covers the latent demand outlook for cardiac rhythm management devices across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in qu...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Cardiac Resynchronization Therapies in India

This study covers the latent demand outlook for cardiac resynchronization therapies across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in ...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Cardiac Pacemakers in the Hospital Segment in India

This study covers the latent demand outlook for cardiac pacemakers in the hospital segment across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each c...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Cardiac Pacemakers in India

This study covers the latent demand outlook for cardiac pacemakers across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the per...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Cardiac Output Monitoring Devices in India

This study covers the latent demand outlook for cardiac output monitoring devices across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in qu...

9/14/2022 | India Outlook 2023

This study covers the latent demand outlook for carpet and rug shampoos across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for carpet and rug shampoos. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of carpet and rug shampoos as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Arcot Manufacturing, Biokleen, Bio-Kleen, Bissell, Core Products Company, CWP Technologies, Evonik Industries, P&G, Powerclean, Procter & Gamble, Reckitt Benckiser Group, Rexair, Rug Doctor, LLC, Siamons International, Spectrum Brands, Techtronic Industries Company, The Clorox Company, and Zep. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for c-arms across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for c-arms. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of c-arms as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AADCO Medical, Assing, BMI Biomedical International, Canon Inc. (Japan), DMS Imaging, EcoRay, Ecotron, Eurocolumbus, GE Healthcare, Hitachi Medical Systems, Hologic, INTERMEDICAL, ITALRAY, Koninklijke Philips, OrthoScan, Philips, Shimadzu Corporation, Siemens AG, STEPHANIX,MS WESTFALIA GMBH, Toshiba, Villa Sistemi Medicali Spa., and Ziehm Imaging. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for cardiovascular therapeutics across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for cardiovascular therapeutics. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of cardiovascular therapeutics as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott Laboratories, Actelion, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo Company, GlaxoSmithKline, Novartis, Pfizer, and Sanofi. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for cardiovascular drugs across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for cardiovascular drugs. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of cardiovascular drugs as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott Laboratories, Ablative Solutions, Astellas Pharma, AstraZeneca, Bayer, Biovail, Boehringer Ingelheim, Bristol-Myers Squibb, Curemark, Daiichi Sankyo, Eli Lilly and Company, F. Hoffmann-La Roche, Gilead Sciences, Inc., Janssen Pharmaceuticals, Johnson & Johnson, Lupin Atlantis Holdings, Merck, Mylan Specialty, Nippon Shinyaku Company, Novartis, Otsuka Pharmaceutical Company, Par Pharmaceutical, Pfizer, Phasebio Pharmaceuticals, Relypsa, Roche Holdings, Sanofi, Silvergate Pharmaceuticals, Takeda Pharmaceutical Company, TSH Biopharm, United Therapeutics, and Vectus Biosystems. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for cardiac safety services across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for cardiac safety services. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of cardiac safety services as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Banook Group, BioClinica, BioTelemetry, Biotrial, Celerion, Certara, ERT, IQVIA, LabCorp, Laboratory Corporation of America Holdings, Medpace, Ncardia, Pharmaceutical Product Development, PhysioStim, PPD, Richmond Pharmacology, SGS SA, and Shanghai Medicilon, Inc.. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for cardiac rhythm management devices across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for cardiac rhythm management devices. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of cardiac rhythm management devices as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott, Abiomed, AliveCor, Altera, Asahi Kasei Corporation, Berlin Heart, Biotronik, Boston Scientific Corporation, BPL Medical Technologies, Cardiac Science, CU Medical Systems, Defibtech, GE Healthcare, Hill-Rom Holdings, Inc., Koninklijke Philips, lepumedical., LivaNova, Medtronic, MicroPort Scientific Corporation, Nihon Kohden Corporation, Osypka Medical, Physio Control, Schiller, Shree Pacetronix, Sorin, St Jude Medical, Stryker, and Zoll Medical. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for cardiac resynchronization therapies across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for cardiac resynchronization therapies. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of cardiac resynchronization therapies as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott, Aetna, BG Medicine, Biotronik, Boston Scientific Corporation, Cook, Elkem Silicones, Johnson & Johnson, LivaNova, MEDICO, Medtronic, Merit Medical Systems, MicroPort Scientific Corporation, and Rodman Media.. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for cardiac pacemakers in the hospital segment across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for cardiac pacemakers in the hospital segment. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of cardiac pacemakers in the hospital segment as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott Laboratories, Biotronik, Boston Scientific Corporation, Lepu Medical, LivaNova, Medico S.p.A. (Italy), Medtronic, OSCOR, Osypka Medical, and Pacetronix. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for cardiac pacemakers across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for cardiac pacemakers. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of cardiac pacemakers as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott, BIOHEART, Biosensors International Group, Biotronik, Boston Scientific, Cardinal Health, CARDIOROBOTICS, Inc., Cook, Cordis, GE Healthcare, Integer Holdings, Lepu Medical, LivaNova, MEDICO, MEDICOWEB, Medline Industries, Medtronic, MicroPort, OSCOR, Osypka Medical, Pacetronix, Qinming Medical, Shree Pacetronix, Sorin Group, St. Jude Medical, USCOME, Ltd., Vitatron, and Zoll Medical. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for cardiac output monitoring devices across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for cardiac output monitoring devices. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of cardiac output monitoring devices as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Baxter International, CNSystems Medizintechnik, Deltex Medical Group, Edward Lifesciences, GE Healthcare, ICU Medical, LiDCO Group, Osypka Medical, and Uscom. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

LATEST REPORTS

PRESS RELEASES

Use Code

SDMR20

Purchase any report

AVAIL FLAT DISCOUNT